Literature DB >> 19701228

Pharmacology: defining the optimal dose of a new drug: a crucial decision.

Hiddo Lambers Heerspink, Dick de Zeeuw.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19701228     DOI： 10.1038/nrneph.2009.111

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  6 in total

1.  Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?

Authors:  Dick de Zeeuw; Hiddo Lambers-Heerspink
Journal:  J Am Soc Nephrol       Date:  2009-03-11       Impact factor: 10.121

2.  Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.

Authors:  A Benigni; V Colosio; C Brena; I Bruzzi; T Bertani; G Remuzzi
Journal:  Diabetes       Date:  1998-03       Impact factor: 9.461

3.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Authors:  René R Wenzel; Thomas Littke; Susan Kuranoff; Christiane Jürgens; Heike Bruck; Eberhard Ritz; Thomas Philipp; Anna Mitchell
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

4.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

5.  Nephroprotective effect of bosentan in diabetic rats.

Authors:  Alessandro Cosenzi; Elena Bernobich; Roberto Trevisan; Neva Milutinovic; Annamaria Borri; Giuseppe Bellini
Journal:  J Cardiovasc Pharmacol       Date:  2003-12       Impact factor: 3.105

Review 6.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546
  6 in total
  4 in total

1.  Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.

Authors:  Jamo Hoekman; Hiddo J Lambers Heerspink; Giancarlo Viberti; Damien Green; Johannes F E Mann; Dick de Zeeuw
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 2.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

3.  Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Authors:  Bauke Schievink; Dick de Zeeuw; Paul A Smink; Dennis Andress; John J Brennan; Blai Coll; Ricardo Correa-Rotter; Fan Fan Hou; Donald Kohan; Dalane W Kitzman; Hirofumi Makino; Hans-Henrik Parving; Vlado Perkovic; Giuseppe Remuzzi; Sheldon Tobe; Robert Toto; Jarno Hoekman; Hiddo J Lambers Heerspink
Journal:  Eur J Prev Cardiol       Date:  2015-07-30       Impact factor: 7.804

Review 4.  Monitoring kidney function and albuminuria in patients with diabetes.

Authors:  Hiddo J Lambers Heerspink; Frank A Holtkamp; Dick de Zeeuw; Mordchai Ravid
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.